Revolutionizing Behavioral Health Research Through Philanthropy
The Vail Health Behavioral Health Innovation Center is ushering in a new era of behavioral health research, treatment, and education.
Vail Health’s Pioneering Study of Psilocybin’s Effects on Depression Kicks off Next Month
(Vail Daily) In April, Vail Health’s Behavioral Health Innovation Center will kick off the second of two studies aimed at targeting depression. The OPTIMIZE study will examine the impacts of psilocybin, the active ingredient in psychedelic mushrooms, on people with major depressive disorder.
OPTIMIZE Study to Examine Impact of Psilocybin on Depression
The OPTIMIZE Study will explore innovative methods to amplify the effects of psilocybin on depression and anxiety through the co-administration of non-invasive vagus nerve stimulation.
What Experts Say About Taking Psilocybin as an Alternative Treatment for Depression
(CNN) For a good number of people antidepressants have been a blessing, at least at the beginning of treatment, but for up to a third of depressed patients, antidepressants fail to work at all, said Dr. Charles Raison.
Depression: Five Million Americans May Benefit From Psychedelic Therapy
(Newsweek) Millions of Americans struggling with depression could benefit from the active ingredient in magic mushrooms, new research suggests. However, approval of such treatments will depend on the U.S. Food and Drug Administration (FDA).